Letters, Testimony & Comments

BIO submits letters, testimony, and comments to government and regulatory bodies throughout the United States and around the world.

Featured Letters, Testimony, & Comments
BIO Comments to FDA on Alternative Tools:…
BIO provided general comments and recommended edits Re: FDA-2023-D-3031
Letter to House and Senate Judiciary Committee…
BIO joins 30 other national trade associations in speaking out against unprecedented and burdensome FTC-DOJ regulation of mergers
BIO letter to FDA on Scientific Challenges and…
BIO submits comments in response to the agency’s request for information (FDA-2023-N-3742)
All Letters, Testimony & Comments
  • Show All
October 10, 2023
In response to their request for information, BIO submitted these comments, including line-by-line recommended edits.
September 29, 2023
BIO submitted comments to DoD, GSA, and NASA on the Proposed Rule to amend and restructure regulations on environmental and sustainability procurement (FAR Case 2022-006, Docket No. 2022-0006, Sequence No. 1 RIN 9000-AO43)
September 27, 2023
Comments on Revised HSR Premerger Notification and Report Form 16 CFR Parts 801-803—Hart-Scott-Rodino Coverage, Exemption, and Transmittal Rules, Project No. P239300
September 20, 2023
BIO Board Vice Chair and CEO of Amicus Therapeutics testified that the drug price controls in the Inflation Reduction Act harm drug research and development.
September 11, 2023
BIO joined with other groups in writing House and Senate Agriculture Committee leaders in support of agricultural research (FFAR) funding in the farm bill. 
August 3, 2023
In response to the agency's request for information (Docket No. FDA-2023-N-0743-0002), BIO provides detailed comments.
August 1, 2023
BIO provides detailed comments in advance of the July 31, 2023 NIH Workshop, “Transforming Discoveries into Products: Maximizing NIH’s Levers to Catalyze Technology Transfer.
July 28, 2023
In response to a Request for Information (RFI) from the Senate 340B Bipartisan Working Group, BIO submitted detailed comments on the current status of the program and suggestions for improvements.